GLP-1-Based Therapies for Cardiovascular Risk Reduction in Kazakhstan: Evidence, Affordability, Equity and Implementation Considerations
5 affiliations
- 1National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan
- 2University Medical Center, Nazarbayev University, Astana 010000, Kazakhstan
- 3Professor G.V. Tsoi Scientific and Educational Center of Surgery, Astana Medical University, Astana 010000, Kazakhstan
- 4Medical Center “Sultan-Medicus”, Almaty 050000, Kazakhstan
- 5City Polyclinic No. 2, Taraz 080000, Kazakhstan
Abstract
Cardiovascular disease (CVD) remains the leading cause of mortality worldwide and is the principal cause of death in low- and middle-income countries. Although cardiovascular outcome trials have established the benefits of Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) in reducing major adverse cardiovascular events, the translation of this evidence into routine clinical practice in Central Asia remains limited and underexplored. Specifically, in Kazakhstan, despite measurable improvements in cardiac infrastructure over the past decade, critical gaps persist in early diagnosis, cardiometabolic risk stratification, and the integration of newer pharmacological strategies into routine practice. In this review, we aim to evaluate the potential role of GLP-1-based therapies within the current cardiovascular prevention landscape in Kazakhstan. It also synthesizes current mechanistic evidence and findings from major clinical trials supporting the use of GLP-1RAs as cardiometabolic agents with potential cardiovascular benefits. Furthermore, we examine the practical factors that may influence their adoption within Kazakhstan’s health system, including accessibility, affordability, clinician preparedness, prescribing capacity, regulatory considerations, and policy integration. By integrating evidence from cardiovascular outcome trials, clinical studies, and health-system perspectives, this review seeks to provide a balanced assessment of the potential contribution of GLP-1-based therapies to cardiovascular risk reduction in Kazakhstan while identifying priorities for future research, implementation strategies, and health policy development.
Related
- Systemic Therapies in Advanced Adrenocortical Carcinoma: Current Standards, Emerging Strategies, and Practical Considerations
- Building a PET/CT Program in Sub-Saharan Africa: A Health-System Framework for Financing, Affordability, and Sustainable Implementation
- Seasonal Hip Strength Monitoring in Division I Women’s Ice Hockey with Strength Ratios and Implementation Considerations
- Focused ethnography protocol for exploring burn pain management practices in clinical settings: methodological considerations and implementation framework.
- Short-term effects of ambient PM₂.₅ exposure on cardiovascular mortality in Almaty, Kazakhstan
BibTeX
@article{berikkhanova2026glp1based,
title = {{GLP-1-Based Therapies for Cardiovascular Risk Reduction in Kazakhstan: Evidence, Affordability, Equity and Implementation Considerations}},
author = {Kulzhan Berikkhanova and Isah Inuwa and Yessenkhan Sultan and Nurzhan Berikkhanov and Saule Rakhimova and Ainur Akilzhanova},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15208190},
url = {https://www.mdpi.com/2077-0383/15/20/8190},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - GLP-1-Based Therapies for Cardiovascular Risk Reduction in Kazakhstan: Evidence, Affordability, Equity and Implementation Considerations
AU - Kulzhan Berikkhanova
AU - Isah Inuwa
AU - Yessenkhan Sultan
AU - Nurzhan Berikkhanov
AU - Saule Rakhimova
AU - Ainur Akilzhanova
PY - 2026
DA - 2026/10/01
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15208190
UR - https://www.mdpi.com/2077-0383/15/20/8190
AB - Cardiovascular disease (CVD) remains the leading cause of mortality worldwide and is the principal cause of death in low- and middle-income countries. Although cardiovascular outcome trials have established the benefits of Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) in reducing major adverse cardiovascular events, the translation of this evidence into routine clinical practice in Central Asia remains limited and underexplored. Specifically, in Kazakhstan, despite measurable improvements in cardiac infrastructure over the past decade, critical gaps persist in early diagnosis, cardiometabolic risk stratification, and the integration of newer pharmacological strategies into routine practice. In this review, we aim to evaluate the potential role of GLP-1-based therapies within the current cardiovascular prevention landscape in Kazakhstan. It also synthesizes current mechanistic evidence and findings from major clinical trials supporting the use of GLP-1RAs as cardiometabolic agents with potential cardiovascular benefits. Furthermore, we examine the practical factors that may influence their adoption within Kazakhstan’s health system, including accessibility, affordability, clinician preparedness, prescribing capacity, regulatory considerations, and policy integration. By integrating evidence from cardiovascular outcome trials, clinical studies, and health-system perspectives, this review seeks to provide a balanced assessment of the potential contribution of GLP-1-based therapies to cardiovascular risk reduction in Kazakhstan while identifying priorities for future research, implementation strategies, and health policy development.
SN - 2077-0383
ER -